Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-FTSE 100 flat as Vodafone loss offsets gains in banks; Oxford Biomedica shines

Tue, 18th May 2021 09:23

(For a Reuters live blog on U.S., UK and European stock
markets, click LIVE/ or type LIVE/ in a news window)

* Oxford Biomedica rises on robust outlook

* Vodafone drops after missing earnings expectations

* FTSE 100 up 0.2%, FTSE 250 adds 0.6%
(Updates with market close)

By Shivani Kumaresan and Devik Jain

May 18 (Reuters) - London's FTSE 100 was little changed on
Tuesday as poor earnings by Vodafone offset gains in bank
stocks, while better-than-expected jobs data strengthened views
of a stronger economic recovery from a pandemic-driven crash
last year.

The blue-chip index rose 0.02%, with banks, mainly
HSBC Holdings, Lloyds Banking Group and
Standard Chartered gaining between 0.8% and 1.5%.

Consumer discretionary stocks, including Compass Group
, Kingfisher and Just Eat Takeaway.com
also provided the biggest boost to the index.

Mobile operator Vodafone Group fell 8.9% on
reporting a 1.2% drop in annual adjusted earnings, as COVID-19
hit roaming revenue and handset sales.

The domestically focussed mid-cap FTSE 250 index
climbed 0.5%.

Britain's unemployment rate fell again, to 4.8% between
January and March, and hiring rose further in April, according
to data that showed employers gearing up for the easing of
coronavirus curbs.

"A third consecutive month of falling unemployment suggests
the peak rate caused by the pandemic wasn't as high as feared",
said Sophie Griffiths, Market Analyst, UK & EMEA at OANDA.

"While the furlough scheme has succeeded in preventing a
wave of redundancies, there is little doubt the jobless rate
will rise again when it concludes in September."

Britain extended its huge job-protecting furlough programme
by five months until the end of September, covering about one in
five private-sector employees who receive 80% of their salary
for hours not worked.

The FTSE 100 has gained nearly 9.4% year-to-date as
investors flocked to energy, materials and banking stocks that
are seen benefiting the most from a stronger economic recovery
due to speedy COVID-19 vaccinations and government support.

Fund managers loaded up on UK stocks and cut exposure to
technology stocks as rising inflation and "taper tantrum" fears
leave growth stocks vulnerable to pull-backs, Bank of America's
May fund manager survey released on Tuesday found.

Among other stocks, Oxford Biomedica gained 10.4%,
to the top of the mid-cap index after it doubled the revenue
expectation from its COVID-19 vaccine supply deal with drugmaker
AstraZeneca.

Imperial Brands rose 1.5% after the tobacco company
reiterated its full-year outlook.
(Reporting by Shivani Kumaresan and Devik Jain in Bengaluru;
editing by Uttaresh.V and Jonathan Oatis)

More News
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.